4.6 Article

Proteomic discovery of substrates of the cardiovascular protease ADAMTS7

Journal

JOURNAL OF BIOLOGICAL CHEMISTRY
Volume 294, Issue 20, Pages 8037-8045

Publisher

AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
DOI: 10.1074/jbc.RA119.007492

Keywords

ADAMTS; substrate specificity; proteolysis; tissue inhibitor of metalloproteinase (TIMP); proteolytic enzyme; ADAMTS7; autolysis; cleavage sites; LTBP4; TIMP-4

Funding

  1. British Heart Foundation [PG/18/19/33584]
  2. Imperial College London
  3. Fonds De La Recherche Scientifique-FNRS Grant [7.6536.18]
  4. Fonds Leon Fredericq
  5. ULiege

Ask authors/readers for more resources

The protease ADAMTS7 functions in the extracellular matrix (ECM) of the cardiovascular system. However, its physiological substrate specificity and mechanism of regulation remain to be explored. To address this, we conducted an unbiased substrate analysis using terminal amine isotopic labeling of substrates (TAILS). The analysis identified candidate substrates of ADAMTS7 in the human fibroblast secretome, including proteins with a wide range of functions, such as collagenous and noncollagenous extracellular matrix proteins, growth factors, proteases, and cell-surface receptors. It also suggested that autolysis occurs at Glu-729-Val-730 and Glu-732-Ala-733 in the ADAMTS7 Spacer domain, which was corroborated by N-terminal sequencing and Western blotting. Importantly, TAILS also identified proteolysis of the latent TGF--binding proteins 3 and 4 (LTBP3/4) at a Glu-Val and Glu-Ala site, respectively. Using purified enzyme and substrate, we confirmed ADAMTS7-catalyzed proteolysis of recombinant LTBP4. Moreover, we identified multiple additional scissile bonds in an N-terminal linker region of LTBP4 that connects fibulin-5/tropoelastin and fibrillin-1-binding regions, which have an important role in elastogenesis. ADAMTS7-mediated cleavage of LTBP4 was efficiently inhibited by the metalloprotease inhibitor TIMP-4, but not by TIMP-1 and less efficiently by TIMP-2 and TIMP-3. As TIMP-4 expression is prevalent in cardiovascular tissues, we propose that TIMP-4 represents the primary endogenous ADAMTS7 inhibitor. In summary, our findings reveal LTBP4 as an ADAMTS7 substrate, whose cleavage may potentially impact elastogenesis in the cardiovascular system. We also identify TIMP-4 as a likely physiological ADAMTS7 inhibitor.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Multidisciplinary Sciences

Exosite inhibition of ADAMTS-5 by a glycoconjugated arylsulfonamide

Salvatore Santamaria, Doretta Cuffaro, Elisa Nuti, Lidia Ciccone, Tiziano Tuccinardi, Francesca Liva, Felicia D'Andrea, Rens de Groot, Armando Rossello, Josefin Ahnstrom

Summary: ADAMTS-5 is a key protease involved in the turnover of proteoglycans, with dysregulated activity linked to osteoarthritis. A new class of sugar-based arylsulfonamides was designed based on ADAMTS-5's ability to bind beta-N-acetyl-D-glucosamine. The most promising compound, 4b, showed high selectivity over ADAMTS-4 as a non-zinc binding inhibitor targeting a previously unknown substrate-binding site critical for substrate recognition.

SCIENTIFIC REPORTS (2021)

Editorial Material Biochemistry & Molecular Biology

Editorial: ADAM, ADAMTS and Astacin Proteases: Challenges and Breakthroughs in the -Omics Era

Kazuhiro Yamamoto, Rens de Groot, Simone Dario Scilabra, Hang Fai Kwok, Salvatore Santamaria

FRONTIERS IN MOLECULAR BIOSCIENCES (2021)

Article Hematology

Metalloproteinase inhibition reduces AML growth, prevents stem cell loss, and improves chemotherapy effectiveness

Chiara Pirillo, Flora Birch, Floriane S. Tissot, Sara Gonzalez Anton, Myriam Haltalli, Valentina Tini, Isabella Kong, Ben Partridge, Constandina Pospori, Karen Keeshan, Salvatore Santamaria, Edwin Hawkins, Brunangelo Falini, Andrea Marra, Delfim Duarte, Chiu Fan Lee, Edward Roberts, Cristina Lo Celso

Summary: By studying an experimental model of AML, it was found that AML may directly affect healthy cells through damaged blood vessels. By inhibiting the activity of matrix metalloproteinases (MMPs), the spread and invasion of AML can be reduced, the retention of healthy hematopoietic stem cells (HSPCs) in the bone marrow can be increased, and patient survival can be extended. This suggests that MMP inhibition could be a promising complementary therapy.

BLOOD ADVANCES (2022)

Article Hematology

Laminin G1 residues of protein S mediate its TFPI cofactor function and are competitively regulated by C4BP

Adrienn Teraz-Orosz, Magdalena Gierula, Anastasis Petri, David Jones, Renos Keniyopoullos, Patricia Badia Folgado, Salvatore Santamaria, James T. B. Crawley, David A. Lane, Josefin Ahnstrom

Summary: Protein S is a cofactor that enhances the inhibition of factor XIII activity and generation by TFPI alpha. The interaction between TFPI alpha and protein S is critical for this enhancement, and binding of C4BP to protein S LG1 abolishes the TFPI cofactor function. The amino acids involved in TFPI alpha enhancement and the mechanisms behind the reduced TFPI cofactor function of C4BP-bound protein S were investigated. It was found that Lys255, Glu257, Asp287, Arg410, Lys423, and Glu424 of protein S are critical for its function, and binding of the C4BP beta-chain blocks this function.

BLOOD ADVANCES (2022)

Article Hematology

Alterations in B- and circulating T-follicular helper cell subsets in immune thrombotic thrombocytopenic purpura

Jin-Sup Shin, Maryam Owais Subhan, Geraldine Cambridge, Yanping Guo, Rens de Groot, Marie Scully, Mari Thomas

Summary: Acute iTTP is characterized by dysregulation of B- and cTfh cell homeostasis with depletion of post-GC memory cells and cTfh cells and increased plasmablasts. Changes in CD80 expression on B cells further suggest altered interactions with T cells.

BLOOD ADVANCES (2022)

Article Biochemistry & Molecular Biology

A top-down approach to uncover the hidden ligandome of low-density lipoprotein receptor-related protein 1 in cartilage

Kazuhiro Yamamoto, Carsten Scavenius, Maria M. Meschis, Abdulrahman M. E. Gremida, Emilie H. Mogensen, Ida B. Thogersen, Simone Bonelli, Simone D. Scilabra, Anders Jensen, Salvatore Santamaria, Josefin Ahnstrom, George Bou-Gharios, Jan J. Enghild, Hideaki Nagase

Summary: This study investigates the role of low-density lipoprotein receptor-related protein 1 (LRP1) in the endocytosis process of articular cartilage. By analyzing the LRP1 interactome, the researchers identified numerous ligand candidates and confirmed their direct binding to LRP1. They also found that inhibition of LRP1-ligand interaction resulted in cell death and alterations in the secretome and transcriptional profile of human chondrocytes. The study highlights the specificity and extent of the chondrocyte LRP1 ligandome and identifies potential new therapeutic targets for osteoarthritis.

MATRIX BIOLOGY (2022)

Article Hematology

Delayed normalization of ADAMTS13 activity in acute thrombotic thrombocytopenic purpura in the caplacizumab era

Nithya Prasannan, Mari Thomas, Matthew Stubbs, John-Paul Westwood, Rens de Groot, Deepak Singh, Marie Scully

Summary: The benefits of caplacizumab in acute immune-mediated thrombotic thrombocytopenic purpura (iTTP) are well established. Delayed normalization of ADAMTS13 activity (>30%) was observed in a subgroup treated with caplacizumab, not seen in the precaplacizumab era. Patients treated with caplacizumab achieved ADAMTS13 activity >30% later than those without caplacizumab, and extended use of caplacizumab was associated with decreased ADAMTS13 activity response.

BLOOD (2023)

Letter Hematology

Unusually high ADAMTS13 activity in a patient with congenital thrombotic thrombocytopenic purpura

Maryam Owais Subhan, Rens de Groot, Marie Scully

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Article Chemistry, Medicinal

Targeting Aggrecanases for Osteoarthritis Therapy: From Zinc Chelation to Exosite Inhibition

Doretta Cuffaro, Lidia Ciccone, Armando Rossello, Elisa Nuti, Salvatore Santamaria

Summary: Osteoarthritis is a common degenerative joint disease. ADAMTS4 and ADAMTS5, members of the ADAMTS family, were identified in 1999 as the enzymes responsible for aggrecan degradation in cartilage. Zinc-chelating inhibitors targeting the active site showed disappointing results, leading to the exploration of exosite inhibitors. However, the lack of structural and functional data on aggrecanase exosites has hampered their potential development.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

Article Biochemistry & Molecular Biology

The C-terminal domains of ADAMTS1 contain exosites involved in its proteoglycanase activity

Alexander Frederick Minns, Yawei Qi, Kazuhiro Yamamoto, Karen Lee, Salvatore Santamaria

Summary: ADAMTS1 is a protease involved in various physiological processes, and it interacts with multiple proteoglycan substrates. The proteoglycanase activity of ADAMTS1 is weaker than other family members, and the spacer and cysteine-rich domains are major determinants of its function. Additionally, these C-terminal domains are also involved in the proteolysis of other proteoglycans.

JOURNAL OF BIOLOGICAL CHEMISTRY (2022)

Review Biochemistry & Molecular Biology

The Role of ADAMTS Proteoglycanases in Thoracic Aortic Disease

Marsioleda Kemberi, Yousuf Salmasi, Salvatore Santamaria

Summary: Thoracic aortic aneurysm and dissection (TAAD) are complex diseases that are difficult to diagnose early. The role of ADAMTSs in thoracic aortic disease and their potential use as biomarkers for diagnosis and disease progression are discussed in this review.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Hematology

Autoantibodies enhance ADAMTS-13 clearance in patients with immune thrombotic thrombocytopenic purpura

Mary I. Underwood, Ferras Alwan, Mari R. Thomas, Marie A. Scully, James T. B. Crawley

Summary: Severe deficiency in ADAMTS-13 and loss of von Willebrand factor-cleaving function can cause microvascular thrombosis in patients with thrombotic thrombocytopenic purpura (TTP). Immune-mediated TTP (iTTP) is characterized by anti-ADAMTS-13 immunoglobulin G antibodies that inhibit ADAMTS-13 function and/or increase its clearance. Our study aims to investigate the role of antibody-mediated ADAMTS-13 clearance and inhibition in iTTP patients during plasma exchange (PEX) therapy.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2023)

Article Hematology

Analysis of thrombogenicity under flow reveals new insights into the prothrombotic state of patients with post-COVID syndrome

Adela Constantinescu-Bercu, Anna Kessler, Rens de Groot, Bertina Dragunaite, Melissa Heightman, Toby Hillman, Laura C. Price, Ewan Brennan, Raphael Sivera, Karen Vanhoorelbeke, Deepak Singh, Marie Scully

Summary: This study used a microfluidic assay to investigate the thrombogenicity in patients with PCS and found significant platelet binding in these patients. Compared with the control group, patients with PCS showed increased thrombi volume related to platelet activity, thrombin generation, and VWF activity.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2023)

Article Biochemistry & Molecular Biology

Development of a fluorogenic ADAMTS-7 substrate

Salvatore Santamaria, Frederic Buemi, Elisa Nuti, Doretta Cuffaro, Elena De Vita, Tiziano Tuccinardi, Armando Rossello, Steven Howell, Shahid Mehmood, Ambrosius P. Snijders, Rens de Groot

Summary: ADAMTS-7 extracellular protease is considered a potential therapeutic target for atherosclerosis and coronary artery disease. A novel fluorescence substrate, ATS7FP7, was developed for high-throughput screening of ADAMTS-7 inhibitors, which may accelerate translational studies for treating cardiovascular diseases.

JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2021)

No Data Available